Cargando…

Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions

Although the full primary structures of the alfa and beta subunits of reference r-hFSH-alfa and its biosimilars are identical, cell context-dependent differences in the expressing cell lines and manufacturing process can lead to variations in glycosylation profiles. In the present study, we compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzi, Lucio, Sepe, Nunzio, Migliaccio, Walter, Lanzoni, Ludovica, Iozzino, Luisa, D’Angelo, Fabrizia, Colarusso, Lucia, Montenegro, Susana, Palmese, Angelo, D’Hooghe, Thomas, Ulloa-Aguirre, Alfredo, Koloda, Yulia, Lispi, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223809/
https://www.ncbi.nlm.nih.gov/pubmed/35743204
http://dx.doi.org/10.3390/ijms23126762
_version_ 1784733216732610560
author Manzi, Lucio
Sepe, Nunzio
Migliaccio, Walter
Lanzoni, Ludovica
Iozzino, Luisa
D’Angelo, Fabrizia
Colarusso, Lucia
Montenegro, Susana
Palmese, Angelo
D’Hooghe, Thomas
Ulloa-Aguirre, Alfredo
Koloda, Yulia
Lispi, Monica
author_facet Manzi, Lucio
Sepe, Nunzio
Migliaccio, Walter
Lanzoni, Ludovica
Iozzino, Luisa
D’Angelo, Fabrizia
Colarusso, Lucia
Montenegro, Susana
Palmese, Angelo
D’Hooghe, Thomas
Ulloa-Aguirre, Alfredo
Koloda, Yulia
Lispi, Monica
author_sort Manzi, Lucio
collection PubMed
description Although the full primary structures of the alfa and beta subunits of reference r-hFSH-alfa and its biosimilars are identical, cell context-dependent differences in the expressing cell lines and manufacturing process can lead to variations in glycosylation profiles. In the present study, we compared the structural features of reference r-hFSH-alfa with those of five biosimilar preparations approved in different global regions outside Europe (Primapur(®), Jin Sai Heng(®), Follitrope(®), Folisurge(®), and Corneumon(®)) with respect to glycosylation, macro- and microheterogeneity, and other post-translational modifications and higher order structure. The mean proportion of N-glycosylation-site occupancy was highest in reference r-hFSH-alfa, decreasing sequentially in Primapur, Jin Sai Heng, Corneumon, Follisurge and Follitrope, respectively. The level of antennarity showed slightly higher complexity in Corneumon, Primapur and Follitrope versus reference r-hFSH-alfa, whereas Jin Sai Heng and Folisurge were aligned with reference r-hFSH-alfa across all N-glycosylation sites. Sialylation level was higher in Corneumon and Follitrope, but small differences were detected in other biosimilar preparations compared with reference r-hFSH-alfa. Jin Sai Heng showed higher levels of N-glyconeuramic acid than the other preparations. Minor differences in oxidation levels were seen among the different products. Therefore, in summary, we identified var ious differences in N-glycosylation occupancy, antennarity, sialylation and oxidation between reference r-hFSH-alfa and the biosimilar preparations analyzed.
format Online
Article
Text
id pubmed-9223809
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92238092022-06-24 Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions Manzi, Lucio Sepe, Nunzio Migliaccio, Walter Lanzoni, Ludovica Iozzino, Luisa D’Angelo, Fabrizia Colarusso, Lucia Montenegro, Susana Palmese, Angelo D’Hooghe, Thomas Ulloa-Aguirre, Alfredo Koloda, Yulia Lispi, Monica Int J Mol Sci Article Although the full primary structures of the alfa and beta subunits of reference r-hFSH-alfa and its biosimilars are identical, cell context-dependent differences in the expressing cell lines and manufacturing process can lead to variations in glycosylation profiles. In the present study, we compared the structural features of reference r-hFSH-alfa with those of five biosimilar preparations approved in different global regions outside Europe (Primapur(®), Jin Sai Heng(®), Follitrope(®), Folisurge(®), and Corneumon(®)) with respect to glycosylation, macro- and microheterogeneity, and other post-translational modifications and higher order structure. The mean proportion of N-glycosylation-site occupancy was highest in reference r-hFSH-alfa, decreasing sequentially in Primapur, Jin Sai Heng, Corneumon, Follisurge and Follitrope, respectively. The level of antennarity showed slightly higher complexity in Corneumon, Primapur and Follitrope versus reference r-hFSH-alfa, whereas Jin Sai Heng and Folisurge were aligned with reference r-hFSH-alfa across all N-glycosylation sites. Sialylation level was higher in Corneumon and Follitrope, but small differences were detected in other biosimilar preparations compared with reference r-hFSH-alfa. Jin Sai Heng showed higher levels of N-glyconeuramic acid than the other preparations. Minor differences in oxidation levels were seen among the different products. Therefore, in summary, we identified var ious differences in N-glycosylation occupancy, antennarity, sialylation and oxidation between reference r-hFSH-alfa and the biosimilar preparations analyzed. MDPI 2022-06-17 /pmc/articles/PMC9223809/ /pubmed/35743204 http://dx.doi.org/10.3390/ijms23126762 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Manzi, Lucio
Sepe, Nunzio
Migliaccio, Walter
Lanzoni, Ludovica
Iozzino, Luisa
D’Angelo, Fabrizia
Colarusso, Lucia
Montenegro, Susana
Palmese, Angelo
D’Hooghe, Thomas
Ulloa-Aguirre, Alfredo
Koloda, Yulia
Lispi, Monica
Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions
title Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions
title_full Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions
title_fullStr Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions
title_full_unstemmed Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions
title_short Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions
title_sort comparative assessment of the structural features of originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilar preparations approved in non-european regions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223809/
https://www.ncbi.nlm.nih.gov/pubmed/35743204
http://dx.doi.org/10.3390/ijms23126762
work_keys_str_mv AT manzilucio comparativeassessmentofthestructuralfeaturesoforiginatorrecombinanthumanfollitropinalfaversusrecombinanthumanfollitropinalfabiosimilarpreparationsapprovedinnoneuropeanregions
AT sepenunzio comparativeassessmentofthestructuralfeaturesoforiginatorrecombinanthumanfollitropinalfaversusrecombinanthumanfollitropinalfabiosimilarpreparationsapprovedinnoneuropeanregions
AT migliacciowalter comparativeassessmentofthestructuralfeaturesoforiginatorrecombinanthumanfollitropinalfaversusrecombinanthumanfollitropinalfabiosimilarpreparationsapprovedinnoneuropeanregions
AT lanzoniludovica comparativeassessmentofthestructuralfeaturesoforiginatorrecombinanthumanfollitropinalfaversusrecombinanthumanfollitropinalfabiosimilarpreparationsapprovedinnoneuropeanregions
AT iozzinoluisa comparativeassessmentofthestructuralfeaturesoforiginatorrecombinanthumanfollitropinalfaversusrecombinanthumanfollitropinalfabiosimilarpreparationsapprovedinnoneuropeanregions
AT dangelofabrizia comparativeassessmentofthestructuralfeaturesoforiginatorrecombinanthumanfollitropinalfaversusrecombinanthumanfollitropinalfabiosimilarpreparationsapprovedinnoneuropeanregions
AT colarussolucia comparativeassessmentofthestructuralfeaturesoforiginatorrecombinanthumanfollitropinalfaversusrecombinanthumanfollitropinalfabiosimilarpreparationsapprovedinnoneuropeanregions
AT montenegrosusana comparativeassessmentofthestructuralfeaturesoforiginatorrecombinanthumanfollitropinalfaversusrecombinanthumanfollitropinalfabiosimilarpreparationsapprovedinnoneuropeanregions
AT palmeseangelo comparativeassessmentofthestructuralfeaturesoforiginatorrecombinanthumanfollitropinalfaversusrecombinanthumanfollitropinalfabiosimilarpreparationsapprovedinnoneuropeanregions
AT dhooghethomas comparativeassessmentofthestructuralfeaturesoforiginatorrecombinanthumanfollitropinalfaversusrecombinanthumanfollitropinalfabiosimilarpreparationsapprovedinnoneuropeanregions
AT ulloaaguirrealfredo comparativeassessmentofthestructuralfeaturesoforiginatorrecombinanthumanfollitropinalfaversusrecombinanthumanfollitropinalfabiosimilarpreparationsapprovedinnoneuropeanregions
AT kolodayulia comparativeassessmentofthestructuralfeaturesoforiginatorrecombinanthumanfollitropinalfaversusrecombinanthumanfollitropinalfabiosimilarpreparationsapprovedinnoneuropeanregions
AT lispimonica comparativeassessmentofthestructuralfeaturesoforiginatorrecombinanthumanfollitropinalfaversusrecombinanthumanfollitropinalfabiosimilarpreparationsapprovedinnoneuropeanregions